Results 261 to 270 of about 5,436,787 (348)

Vascular endothelial generating factor pathway in ovarian cancer. [PDF]

J Ovarian Res
Zhao Y, Chen Q, Li J, Liu F, Dong K, Han F.   +5 more
europepmc   +1 more source

SIRT5–RAC2 Axis Drives Monocyte‐to‐Macrophage Differentiation to Promote Inflammatory Injury in Premature Ovarian Insufficiency

Advanced Science, EarlyView.
SIRT5 desuccinylates and stabilizes RAC2, activating CSF1R‐dependent signaling to drive monocyte differentiation into M0 macrophages and their polarization toward pro‐inflammatory M1 phenotypes in CTX‐induced premature ovarian insufficiency. Inhibiting the SIRT5‐RAC2 axis attenuates inflammation, reduces granulosa cell apoptosis, and preserves ...
Wenjing TanTai, Yaqi Li, Shengnan Liu, Minjuan Wu, Zhixiao Liu, Junfeng Jiang, Jingjing Chen, Xiaoding Xu, Li Li, Chaoqun Li, Fang Zhao, Ye Liu, Haitao Ni, Tengfei Zhang, Mingjuan Xu, Chaofeng Han   +15 more
wiley   +1 more source

Spectrum and Impact of Mitochondrial DNA Mutations in Ovarian Cancer. [PDF]

Int J Mol Sci
Low SSP, Greaves L, Silk R, Semple CA, Gourley C.   +4 more
europepmc   +1 more source

Universal Antibody‐Engineered Lipid Nanoparticles Potentiate Chemo‐Immunotherapy Against Triple‐Negative Breast Cancer by Reprogramming Tumor Cell Metabolism

Advanced Science, EarlyView.
A universal ROR1 antibody‐engineered lipid nanoparticle (LNP) is constructed by sequential drug encapsulation and antibody conjugation. The LNP not only enables enhanced chemotherapeutic efficiency by targeting drug delivery and precise localization of deep‐seated tumors through NIR‐II fluorescence imaging, but also remodels immunosuppressive TME ...
Yeneng Dai, Jiaqi Wang, Yu Liu, Guanda Jiao, Yuheng Gu, Yang Liu, Shengyu Fu, Xing Fan, Jialin Li, Ziang Guo, Kam Tong Leung, Lipeng Zhu, Qi Zhao   +12 more
wiley   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source

Artificial intelligence for precision management of epithelial ovarian cancer: a comprehensive review. [PDF]

Front Med (Lausanne)
Liu Q, Zhang C, Li P, Jing R, Bi L, Chen W.   +5 more
europepmc   +1 more source

Ascites circRNA ASCOR Drives Platinum Resistance of High‐Grade Serous Ovarian Cancer by Facilitating RPA1 Nuclear Translocation

Advanced Science, EarlyView.
High‐grade serous ovarian carcinoma (HGSOC) is plagued by platinum resistance, with malignant ascites closely linked to poor outcomes. Here, we identify ASCOR, a circRNA enriched in ascites small extracellular vesicles (sEVs) from platinum‐resistant HGSOC patients, as a predictor of poor survival. ASCOR enhances platinum resistance in vitro and in vivo
Hanyuan Liu, Chenchen Zhu, Xuelin Yao, Yi Liu, Jing Zhu, Yuebo Li, Hanjie Xu, Cheng Peng, Ge Shan, Liang Chen, Ying Zhou   +10 more
wiley   +1 more source

Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers. [PDF]

Clin Transl Med
Lamia MR, Perri E, Baldassarre G, Pignata S, D'Alessio C, Limongello D, Basso-Valentina F.   +6 more
europepmc   +1 more source